News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
728,211 Results
Type
Article (41228)
Company Profile (311)
Press Release (686664)
Multimedia
Podcasts (79)
Webinars (17)
Section
Business (207127)
Career Advice (2034)
Deals (35855)
Drug Delivery (109)
Drug Development (82457)
Employer Resources (175)
FDA (16441)
Job Trends (15076)
News (350325)
Policy (32937)
Tag
Academia (2570)
Accelerated approval (31)
Adcomms (24)
Allergies (134)
Alliances (50261)
ALS (168)
Alzheimer's disease (1653)
Antibody-drug conjugate (ADC) (298)
Approvals (16696)
Artificial intelligence (491)
Autoimmune disease (135)
Automation (34)
Bankruptcy (361)
Best Places to Work (11738)
BIOSECURE Act (20)
Biosimilars (185)
Biotechnology (205)
Bladder cancer (156)
Brain cancer (56)
Breast cancer (619)
Cancer (4669)
Cardiovascular disease (395)
Career advice (1714)
Career pathing (35)
CAR-T (272)
CDC (44)
Celiac Disease (1)
Cell therapy (716)
Cervical cancer (35)
Clinical research (70278)
Collaboration (1636)
Company closure (4)
Compensation (1115)
Complete response letters (50)
COVID-19 (2714)
CRISPR (86)
C-suite (784)
Cystic fibrosis (144)
Data (6034)
Decentralized trials (2)
Denatured (25)
Depression (130)
Diabetes (486)
Diagnostics (6656)
Digital health (40)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (238)
Drug pricing (178)
Drug shortages (28)
Duchenne muscular dystrophy (219)
Earnings (90895)
Editorial (54)
Employer branding (22)
Employer resources (153)
Events (119215)
Executive appointments (970)
FDA (19428)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1421)
Gene editing (188)
Generative AI (40)
Gene therapy (570)
GLP-1 (949)
Government (4656)
Grass and pollen (7)
Guidances (379)
Healthcare (18907)
HIV (53)
Huntington's disease (42)
IgA nephropathy (81)
Immunology and inflammation (238)
Immuno-oncology (49)
Indications (86)
Infectious disease (2968)
Inflammatory bowel disease (184)
Inflation Reduction Act (14)
Influenza (107)
Intellectual property (233)
Interviews (319)
IPO (16822)
IRA (49)
Job creations (3689)
Job search strategy (1436)
JPM (53)
Kidney cancer (15)
Labor market (81)
Layoffs (548)
Leadership (30)
Legal (7974)
Liver cancer (90)
Longevity (13)
Lung cancer (635)
Lymphoma (365)
Machine learning (41)
Management (59)
Manufacturing (751)
MASH (160)
Medical device (13734)
Medtech (13778)
Mergers & acquisitions (20069)
Metabolic disorders (1217)
Multiple sclerosis (153)
NASH (16)
Neurodegenerative disease (303)
Neuropsychiatric disorders (78)
Neuroscience (2833)
Neurotech (1)
NextGen: Class of 2026 (6546)
Non-profit (4521)
Now hiring (63)
Obesity (565)
Opinion (252)
Ovarian cancer (160)
Pain (183)
Pancreatic cancer (218)
Parkinson's disease (271)
Partnered (33)
Patents (471)
Patient recruitment (448)
Peanut (55)
People (59451)
Pharmaceutical (74)
Pharmacy benefit managers (28)
Phase I (21941)
Phase II (30965)
Phase III (22981)
Pipeline (4685)
Policy (270)
Postmarket research (2570)
Preclinical (9321)
Press Release (64)
Prostate cancer (224)
Psychedelics (43)
Radiopharmaceuticals (280)
Rare diseases (777)
Real estate (6041)
Recruiting (70)
Regulatory (24459)
Reports (51)
Research institute (2391)
Resumes & cover letters (351)
Rett syndrome (26)
RNA editing (16)
RSV (74)
Schizophrenia (145)
Series A (232)
Series B (182)
Service/supplier (11)
Sickle cell disease (94)
Special edition (21)
Spinal muscular atrophy (155)
Sponsored (41)
Startups (3658)
State (2)
Stomach cancer (17)
Supply chain (102)
Tariffs (82)
The Weekly (52)
Vaccines (981)
Venture capital (87)
Weight loss (362)
Women's health (80)
Worklife (17)
Date
Last 7 days (347)
Last 30 days (1912)
Last 365 days (30189)
2026 (1799)
2025 (30428)
2024 (35564)
2023 (40489)
2022 (51640)
2021 (56245)
2020 (54472)
2019 (46904)
2018 (35314)
2017 (32519)
2016 (31953)
2015 (38033)
2014 (31864)
2013 (26784)
2012 (28960)
2011 (29624)
2010 (27684)
Location
Africa (746)
Alabama (84)
Alaska (7)
Arizona (303)
Arkansas (14)
Asia (40100)
Australia (6501)
California (10960)
Canada (3203)
China (1081)
Colorado (464)
Connecticut (463)
Delaware (325)
Europe (87336)
Florida (1636)
Georgia (347)
Hawaii (2)
Idaho (61)
Illinois (836)
India (58)
Indiana (508)
Iowa (22)
Japan (402)
Kansas (125)
Kentucky (37)
Louisiana (25)
Maine (72)
Maryland (1364)
Massachusetts (7944)
Michigan (312)
Minnesota (618)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (118)
New Hampshire (77)
New Jersey (2942)
New Mexico (29)
New York (2913)
North Carolina (1466)
North Dakota (8)
Northern California (5313)
Ohio (321)
Oklahoma (20)
Oregon (41)
Pennsylvania (2219)
Puerto Rico (21)
Rhode Island (47)
South America (1115)
South Carolina (62)
South Dakota (1)
Southern California (4255)
Tennessee (169)
Texas (1697)
United States (39127)
Utah (324)
Vermont (1)
Virginia (254)
Washington D.C. (80)
Washington State (906)
West Virginia (4)
Wisconsin (102)
Wyoming (2)
728,211 Results for "ipsen biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
January 14, 2026
·
10 min read
Press Releases
Ipsen – Half year statement – 2025 12 31
January 7, 2026
·
5 min read
Press Releases
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
January 14, 2026
·
8 min read
Press Releases
Ipsen provides update on legacy of Henri Beaufour
December 5, 2025
·
5 min read
Press Releases
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
December 16, 2025
·
4 min read
Press Releases
Ipsen mourns the passing of Henri Beaufour, a founding family Board member
December 1, 2025
·
6 min read
Press Releases
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
December 22, 2025
·
7 min read
Press Releases
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
December 19, 2025
·
7 min read
Press Releases
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
October 22, 2025
·
11 min read
Press Releases
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
September 22, 2025
·
9 min read
1 of 72,822
Next
